Close

Deutsche Bank Resumes Valeant Pharmaceuticals (VRX) at Hold

September 20, 2016 7:08 AM EDT Send to a Friend
Deutsche Bank resumed coverage on Valeant Pharmaceuticals (NYSE: VRX) with a Hold rating and a price target of $30. Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login